122 related articles for article (PubMed ID: 20506947)
1. P53 expression as a prognostic marker in giant cell tumor of bone: a pilot study.
Papanastassiou I; Ioannou M; Papagelopoulos PJ; Arealis G; Mihas C; Iakovidou I; Demertzis N
Orthopedics; 2010 May; 33(5):. PubMed ID: 20506947
[TBL] [Abstract][Full Text] [Related]
2. Differential gene expression in classic giant cell tumours of bone: Tenascin C as biological risk factor for local relapses and metastases.
Pazzaglia L; Conti A; Chiechi A; Novello C; Magagnoli G; Astolfi A; Pession A; Krenacs T; Alberghini M; Picci P; Benassi MS
Histopathology; 2010 Jul; 57(1):59-72. PubMed ID: 20653781
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of surgical margins in head and neck squamous cell carcinoma patients.
Nathan CO; Amirghahri N; Rice C; Abreo FW; Shi R; Stucker FJ
Laryngoscope; 2002 Dec; 112(12):2129-40. PubMed ID: 12461330
[TBL] [Abstract][Full Text] [Related]
4. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.
Oda Y; Yamamoto H; Takahira T; Kobayashi C; Kawaguchi K; Tateishi N; Nozuka Y; Tamiya S; Tanaka K; Matsuda S; Yokoyama R; Iwamoto Y; Tsuneyoshi M
J Pathol; 2005 Dec; 207(4):410-21. PubMed ID: 16177957
[TBL] [Abstract][Full Text] [Related]
5. A case of de novo secondary malignant giant-cell tumor of bone with loss of heterozygosity of p53 gene that transformed within a short-term follow-up.
Saito T; Mitomi H; Suehara Y; Okubo T; Torigoe T; Takagi T; Kaneko K; Yao T
Pathol Res Pract; 2011 Oct; 207(10):664-9. PubMed ID: 21924561
[TBL] [Abstract][Full Text] [Related]
6. Genomic instability in giant cell tumor of bone. A study of 52 cases using DNA ploidy, relocalization FISH, and array-CGH analysis.
Moskovszky L; Szuhai K; Krenács T; Hogendoorn PC; Szendroi M; Benassi MS; Kopper L; Füle T; Sápi Z
Genes Chromosomes Cancer; 2009 Jun; 48(6):468-79. PubMed ID: 19242928
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of TP53 mutation status for adult patients with supratentorial World Health Organization Grade II astrocytoma or oligoastrocytoma: a long-term analysis.
Ständer M; Peraud A; Leroch B; Kreth FW
Cancer; 2004 Sep; 101(5):1028-35. PubMed ID: 15329912
[TBL] [Abstract][Full Text] [Related]
8. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
9. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
10. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
11. [Prognostic relevance of proliferation marker Ki-67 (MIB 1), PCNA and p53 in combined surgically and radiologically treated cancers of the oropharynx and mouth cavity].
Sittel C; Ruiz S; Kvasnicka HM; Volling P; Jungehülsing M; Eckel HE
Laryngorhinootologie; 2000 Feb; 79(2):86-92. PubMed ID: 10738715
[TBL] [Abstract][Full Text] [Related]
12. Bax mutation and overexpression inversely correlate with immature phenotype and prognosis of childhood germ cell tumors.
Addeo R; Crisci S; D'Angelo V; Vincenzi B; Casale F; Pettinato G; Donofrio V; Boldrini R; Alaggio R; Collini P; Bertorelle R; Di Tullio MT; Caraglia M; Terenziani M; Lo Curto M; Indolfi P
Oncol Rep; 2007 May; 17(5):1155-61. PubMed ID: 17390059
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases.
Antonescu CR; Tschernyavsky SJ; Decuseara R; Leung DH; Woodruff JM; Brennan MF; Bridge JA; Neff JR; Goldblum JR; Ladanyi M
Clin Cancer Res; 2001 Dec; 7(12):3977-87. PubMed ID: 11751490
[TBL] [Abstract][Full Text] [Related]
15. Correlation of p53 and the proto-oncogene eIF4E in larynx cancers: prognostic implications.
Nathan CO; Sanders K; Abreo FW; Nassar R; Glass J
Cancer Res; 2000 Jul; 60(13):3599-604. PubMed ID: 10910074
[TBL] [Abstract][Full Text] [Related]
16. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
[TBL] [Abstract][Full Text] [Related]
17. Mutant p53 protein overexpression in women with ipsilateral breast tumor recurrence following lumpectomy and radiation therapy.
Turner BC; Gumbs AA; Carbone CJ; Carter D; Glazer PM; Haffty BG
Cancer; 2000 Mar; 88(5):1091-8. PubMed ID: 10699900
[TBL] [Abstract][Full Text] [Related]
18. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1.
Beck T; Weller EE; Weikel W; Brumm C; Wilkens C; Knapstein PG
Gynecol Oncol; 1995 Apr; 57(1):96-104. PubMed ID: 7705708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
